US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 45.700
- -0.060-0.13%
Close Nov 21 16:00 ET
- 46.150
- +0.450+0.98%
Post 20:01 ET
5.81BMarket Cap15.13P/E (TTM)
46.115High44.800Low1.30MVolume45.850Open45.760Pre Close59.01MTurnover1.03%Turnover Ratio21.76P/E (Static)127.23MShares65.53352wk High12.84P/B5.75BFloat Cap33.15052wk Low--Dividend TTM125.89MShs Float65.533Historical High--Div YieldTTM2.87%Amplitude1.410Historical Low45.465Avg Price1Lot Size
Halozyme Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 34.28%290.08M | 4.67%231.35M | 20.81%195.88M | 25.62%829.25M | 26.75%230.04M | 3.38%216.03M | 45.07%221.04M | 38.25%162.14M | 48.91%660.12M | 77.93%181.5M |
| Operating revenue | 34.28%290.08M | 4.67%231.35M | 20.81%195.88M | 25.62%829.25M | 26.75%230.04M | 3.38%216.03M | 45.07%221.04M | 38.25%162.14M | 48.91%660.12M | 77.93%181.5M |
| Cost of revenue | -9.84%49.43M | -20.90%39.61M | -19.45%28.33M | 38.09%192.36M | 24.16%52.3M | 15.86%54.82M | 47.51%50.07M | 120.89%35.17M | 71.11%139.3M | 95.12%42.12M |
| Gross profit | 49.28%240.66M | 12.15%191.75M | 31.96%167.55M | 22.29%636.89M | 27.53%177.74M | -0.28%161.21M | 44.37%170.97M | 25.27%126.97M | 43.91%520.81M | 73.32%139.38M |
| Operating expense | 6.21%77.46M | -2.61%74.51M | -1.59%72.01M | 18.18%299.32M | 18.25%76.71M | -6.93%72.93M | -9.31%76.51M | 184.86%73.17M | 194.53%253.28M | 171.61%64.87M |
| Selling and administrative expenses | 16.93%41.24M | -8.31%35.71M | -5.95%35.13M | 3.94%149.18M | -0.37%37.61M | 2.33%35.27M | -32.24%38.95M | 170.04%37.36M | 185.21%143.53M | 174.06%37.75M |
| Research and development costs | 6.56%18.46M | 6.65%21.04M | 6.30%19.11M | 14.65%76.36M | -5.45%21.34M | 3.69%17.32M | 27.41%19.73M | 51.68%17.98M | 86.72%66.61M | 123.25%22.57M |
| Depreciation amortization depletion | -12.68%17.76M | -0.41%17.76M | -0.40%17.76M | 70.98%73.77M | 290.20%17.76M | -25.20%20.34M | 56.41%17.84M | --17.84M | --43.15M | --4.55M |
| -Depreciation and amortization | -12.68%17.76M | -0.41%17.76M | -0.40%17.76M | 70.98%73.77M | 290.20%17.76M | -25.20%20.34M | 56.41%17.84M | --17.84M | --43.15M | --4.55M |
| Operating profit | 84.87%163.2M | 24.11%117.24M | 77.58%95.54M | 26.18%337.57M | 35.60%101.04M | 5.99%88.28M | 177.33%94.46M | -28.90%53.8M | -3.03%267.53M | 31.80%74.51M |
| Net non-operating interest income expense | -0.42%-4.52M | -0.67%-4.52M | 0.79%-4.51M | -10.71%-18.76M | -14.22%-5.22M | 40.05%-4.51M | -44.78%-4.49M | -158.27%-4.54M | -125.18%-16.95M | -122.38%-4.57M |
| Non-operating interest expense | 0.42%4.52M | 0.67%4.52M | -0.79%4.51M | 10.71%18.76M | 14.22%5.22M | -40.05%4.51M | 44.78%4.49M | 158.27%4.54M | 125.18%16.95M | 122.38%4.57M |
| Other net income (expense) | -64.01%6.47M | 57.64%5.03M | 67.61%4.99M | 1,871.73%29.52M | 529.11%5.36M | 968.47%17.99M | 437.78%3.19M | 498.19%2.98M | 91.61%-1.67M | 157.40%852K |
| Gain on sale of security | 35.27%6.47M | 57.64%5.03M | 67.61%4.99M | 1,459.94%16.32M | 529.11%5.36M | 646.65%4.79M | 437.78%3.19M | 498.19%2.98M | -5.08%1.05M | 157.40%852K |
| Special income (charges) | --0 | ---- | ---- | 586.73%13.2M | --0 | 586.73%13.2M | ---- | ---- | 87.06%-2.71M | --0 |
| -Less：Restructuring and merger&acquisition | --0 | ---- | ---- | ---13.2M | --0 | ---13.2M | ---- | ---- | --0 | --0 |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -87.06%2.71M | --0 |
| Income before tax | 62.29%165.15M | 26.39%117.74M | 83.83%96.03M | 39.94%348.33M | 42.92%101.18M | 38.06%101.76M | 210.41%93.16M | -29.80%52.24M | 0.16%248.92M | 29.16%70.79M |
| Income tax | 41.22%28.14M | 33.13%24.5M | 52.14%19.21M | 42.63%66.74M | 20.61%15.79M | 65.02%19.92M | 151.19%18.4M | -11.73%12.62M | 130.34%46.79M | 209.44%13.09M |
| Net income | 67.42%137.01M | 24.74%93.25M | 93.92%76.82M | 39.31%281.59M | 47.98%85.39M | 32.78%81.84M | 229.53%74.75M | -34.09%39.62M | -49.81%202.13M | -13.58%57.7M |
| Net income continuous Operations | 67.42%137.01M | 24.74%93.25M | 93.92%76.82M | 39.31%281.59M | 47.98%85.39M | 32.78%81.84M | 229.53%74.75M | -34.09%39.62M | -49.81%202.13M | -13.58%57.7M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 67.42%137.01M | 24.74%93.25M | 93.92%76.82M | 39.31%281.59M | 47.98%85.39M | 32.78%81.84M | 229.53%74.75M | -34.09%39.62M | -49.81%202.13M | -13.58%57.7M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 67.42%137.01M | 24.74%93.25M | 93.92%76.82M | 39.31%281.59M | 47.98%85.39M | 32.78%81.84M | 229.53%74.75M | -34.09%39.62M | -49.81%202.13M | -13.58%57.7M |
| Basic earnings per share | 74.19%1.08 | 28.07%0.73 | 110.34%0.61 | 43.92%2.13 | 51.16%0.65 | 37.78%0.62 | 256.25%0.57 | -34.09%0.29 | -48.25%1.48 | -10.42%0.43 |
| Diluted earnings per share | 72.13%1.05 | 28.57%0.72 | 106.90%0.6 | 45.83%2.1 | 54.76%0.65 | 38.64%0.61 | 250.00%0.56 | -32.56%0.29 | -47.45%1.44 | -8.70%0.42 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data